Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

about

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

Item

http://www.wikidata.org/entity/Q55416207

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

@en

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

@nl

type

Item

label

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

@en

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

@nl

altLabel

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

@en

prefLabel

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

@en

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

@nl

P1476

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Kohei Omatsu

http://www.w3.org/2001/XMLSchema#string

Robert L Coleman

http://www.w3.org/2001/XMLSchema#string

P2860

Susceptibility pathways in Fanconi's anemia and breast cancer

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Integrated genomic analyses of ovarian carcinoma

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer

P304

1758835918778483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758835918778483

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Graziela Z Dal Molin

P577

2018-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29977351

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

6024342

http://www.w3.org/2001/XMLSchema#string